drugset / Trial / NCT04391556
Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
Evaluation of the interest of PET-PSMA imaging potentiated by androgen blockade in patients with biological relapse or persistent biological disease of a localized prostatic adenocarcinoma after initial treatment
Timeline
- Start
- 2020-09-14
- Primary completion
- 2023-05-02
- Completion
- 2024-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Degarelix | Other / unclassified | 120 mg | Subcutaneous |